Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.
[read the full story...]
Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.
[read the full story...]
Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.
[read the full story...]
Michael Ostacher provides a robust appraisal of a recent UK cohort study that suggests bipolar disorder patients taking lithium had reduced self-harm and unintentional injury rates, when compared with patients taking valproate, olanzapine or quetiapine.
[read the full story...]
John Baker summarises an updated Cochrane review on ‘as required’ PRN medication regimens for seriously mentally ill people in hospital, which finds no randomised controlled trials that support this widely used intervention.
[read the full story...]
Murtada Alsaif summarises a recent network meta-analysis, which looks at the efficacy, acceptability and tolerability of antipsychotics for treatment-resistant schizophrenia.
[read the full story...]
Murtada Alsaif summarises a small cohort study that uses shotgun mass spectrometry proteomic profiling to unravel the molecular pathways involved with antipsychotic response in people with schizophrenia.
[read the full story...]
Helen Bould appraises a recent meta-analysis of second-generation antipsychotics for anorexia nervosa, which finds that the drugs don’t lead to weight gain or improve eating disorder symptoms. So why are antipsychotics being used in this group of patients?
[read the full story...]
Tracey Roberts summarises a recent paper that reviews the existing literature concerned with switching antipsychotics in patients with schizophrenia, and goes on to present the ongoing OPTiMiSE RCT in this field, which is due to be published in 2016.
[read the full story...]
John Baker reviews a recent participant-level meta-analysis of six placebo-controlled studies, which looks at the initial severity of schizophrenia and the efficacy of antipsychotics including Olanzapine, Risperidone and Amisulpride.
[read the full story...]
